Capricor Therapeutics Inc (CAPR) to Release Earnings on Wednesday
Capricor Therapeutics Inc (OTCMKTS:CAPR) will be posting its quarterly earnings results on Wednesday, November 8th. Analysts expect Capricor Therapeutics to post earnings of ($0.19) per share for the quarter.
Capricor Therapeutics (OTCMKTS:CAPR) last released its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.02. The company had revenue of $1.00 million for the quarter, compared to analyst estimates of $1.10 million. On average, analysts expect Capricor Therapeutics to post $-0.70 EPS for the current fiscal year and $-0.76 EPS for the next fiscal year.
Shares of Capricor Therapeutics Inc (CAPR) opened at 2.48 on Wednesday. The firm’s 50-day moving average is $2.29 and its 200-day moving average is $1.58. The firm’s market cap is $58.27 million. Capricor Therapeutics Inc has a 12-month low of $0.63 and a 12-month high of $4.25.
COPYRIGHT VIOLATION WARNING: “Capricor Therapeutics Inc (CAPR) to Release Earnings on Wednesday” was originally reported by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another website, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/11/01/capricor-therapeutics-inc-capr-to-release-earnings-on-wednesday.html.
Several research firms have recently commented on CAPR. HC Wainwright set a $2.00 target price on Capricor Therapeutics and gave the company a “buy” rating in a research note on Monday, August 14th. Zacks Investment Research upgraded Capricor Therapeutics from a “hold” rating to a “buy” rating and set a $1.25 target price for the company in a research note on Wednesday, August 16th. Rodman & Renshaw reiterated a “buy” rating and set a $2.15 target price on shares of Capricor Therapeutics in a research note on Saturday, July 22nd. Finally, ValuEngine upgraded Capricor Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Monday, October 2nd.
Capricor Therapeutics Company Profile
Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications.
Receive News & Ratings for Capricor Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.